Abstract Library

#4329 Multivariate survival analyses of 544 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC) given first-line chemotherapy (NORDIC NEC 2)

Introduction: Digestive high-grade neuroendocrine neoplasms (HG-NEN) are rare and consist of neuroendocrine tumours G3 (NET G3) and neuroendocrine carcinomas (NEC). They differ in clinical and molecular characteristics, response to treatment and prognosis. Limited prospective data are available on prognostic factors for survival in patients given first-line chemotherapy outside of clinical trials.

Conference:

Presenting Author:

Authors: Sorbye H, Hjortland G, Vestermark L, Ladekarl M, Svensson J,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, digestive, high-grade, neuroendocrine tumour grade 3,

#3965 Nordic NEC 2: Characteristics and treatment outcome in a prospective cohort of 698 patients with high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)

Introduction: Digestive high-grade (HG) neuroendocrine neoplasms (NEN) are rare with limited data on epidemiology, treatment benefit and survival.

Conference:

Presenting Author:

Authors: Sorbye H, Hjortland G, Vestermark L, Laderkarl M, Svensson J,

Keywords: NEC, NET G3, digestive, chemotherapy, neuroendocrine neoplasms,

#3717 Results of NETest liquid biopsy in high-grade gastroenteropancreatic neuroendocrine neoplasms

Introduction: Molecular blood biomarkers are lacking for high-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN), and morphologically separating between neuroendocrine carcinoma (NEC), neuroendocrine tumors (NET G3), adenocarcinoma and MINEN frequently difficult. The mRNA-based NETest has diagnostic, prognostic and predictive value in neuroendocrine tumors G1-2 but has not been studied in HG GEP-NEN.

Conference:

Presenting Author: Sorbye H

Authors: Sorbye H, Langer S, Hjortland G, Vestermark L, Sundlov A,

Keywords: NETest, high-grade, gastroenteropancreatic, neuroendocrine carcinoma, NET G3, neuroendocrine neoplasm, biomarker,

#3550 Randomized open label phase III study comparing the efficacy and safety of Everolimus followed by chemotherapy with Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)

Introduction: STZ-5FU and everolimus are frontline options for systemic treatment in patients with advanced and progressive pancreatic neuroendocrine tumors (panNETs). Switch between both upon progression is a common strategy, but the best sequence is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Vestermark L, Teulé A, Garcia-Carbonero R,

Keywords: pNET, everolimus, streptozotocin, 5FU, randomized trial,

#1604 Resection of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas: A Nordic Multicenter Study

Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Currently, resection of liver metastases in patients with metastatic GEP-NEC is not recommended. However, the existing data are scarce.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Galleberg R, Knigge U, Janson E, Vestermark L, Haugvik S,

Keywords: neuroendocrine carcinoma, liver metastases, liver surgery, Ki67, survival,